Skip to main content
TheraVet SA logo

TheraVet SA — Investor Relations & Filings

Ticker · ALVET ISIN · BE0974387194 LEI · 984500804EBR3F1EFF71 BR Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2024-09-30 Regulatory Filings
Country BE Belgium
Listing BR ALVET

About TheraVet SA

https://www.egeiro.com/

TheraVet SA is a veterinary biotechnology company specializing in the development and commercialization of treatments for osteoarticular diseases in companion animals. The company focuses on creating a portfolio of pharmaceutical products and solutions designed to manage bone and joint conditions, such as osteoarthritis. Its primary objective is to provide innovative therapeutic options to improve the mobility and quality of life for pets.

Recent filings

Filing Released Lang Actions
30092024_TheraVet_Projet de Transformation Strategique.pdf
Regulatory Filings Classification · 100% confidence The document announces a major strategic transformation involving TheraVet acquiring a human biotech program (related to Idiopathic Pulmonary Fibrosis) from H4Orphan in exchange for issuing new shares. This involves a significant corporate restructuring, a change in business focus (from veterinary to human biotech), and a proposed name change. Crucially, the document states: "L'Opération sera soumise à l'approbation des actionnaires le 17 octobre 2024 lors d'une Assemblée Générale Extraordinaire (AGE)." It also mentions that detailed information is available in the "Rapport Spécial du Conseil d'administration" (Special Report of the Board of Directors) which shareholders must review before voting at the upcoming Extraordinary General Meeting (AGE). Since the document is an announcement detailing a major corporate action that requires shareholder approval via a vote at a general meeting, and it references a detailed report for shareholders, it strongly aligns with the purpose of a Proxy Solicitation & Information Statement (PSI), which solicits votes based on provided information. While it discusses capital changes (SHA) and management changes (MANG), the primary context is seeking shareholder approval for the entire transaction structure, making PSI the most appropriate classification for this type of pre-meeting disclosure.
2024-09-30 French
Inside Information / Operations of the issuer (acquisitions, sales...)
M&A Activity Classification · 99% confidence The document is a press release announcing a major strategic transformation project involving the contribution of H4Orphan's clinical program in idiopathic pulmonary fibrosis to TheraVet in exchange for new shares. It details the terms of the transaction, the associated financing, and the plan to submit the operation for shareholder approval at an Extraordinary General Meeting (EGM) on October 17, 2024. This announcement describes a significant corporate action related to financing, asset contribution, and potential change in business focus, which falls under the category of Capital/Financing Update (CAP). While it mentions an upcoming EGM, the primary focus is the transaction structure and financing, not the voting results (DVA) or the proxy materials (PSI). It is not a full 10-K, IR, or ER, but a specific corporate event announcement.
2024-09-30 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Share Issue/Capital Change Classification · 99% confidence The document announces a major strategic transformation involving TheraVet acquiring a human biotech program (related to Idiopathic Pulmonary Fibrosis) from H4Orphan in exchange for issuing new shares. This involves a significant corporate restructuring, a change in business focus (from veterinary to human biotech), and a proposed name change. Crucially, the document states: "L'Opération sera soumise à l'approbation des actionnaires le 17 octobre 2024 lors d'une Assemblée Générale Extraordinaire (AGE)." It also mentions that detailed information is available in the "Rapport Spécial du Conseil d'administration" (Special Report of the Board of Directors) which shareholders must review before voting at the upcoming Extraordinary General Meeting (AGE). Since the document is an announcement detailing a major corporate action that requires shareholder approval via a vote at a general meeting, and it references a detailed report for shareholders, it strongly aligns with the purpose of a Proxy Solicitation & Information Statement (PSI), which solicits votes based on provided information. While it discusses capital changes (SHA) and management changes (MANG), the primary context is seeking shareholder approval for the entire transaction structure, making PSI the most appropriate classification for this type of pre-meeting disclosure.
2024-09-30 French
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a press release from TheraVet announcing the completion of two capital increases resulting from the conversion of convertible bonds ('obligations convertibles') into new shares, totaling €135,000. This action directly relates to the company's financing activities and changes in its capital structure. Based on the provided definitions, the most appropriate category is 'Capital/Financing Update' (CAP), as it details a specific fundraising/capital structure event.
2024-09-26 French
20240912_Communqiue de Presse _TheraVet_1H2024 resultats.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2024 (1er semestre 2024) for TheraVet. It contains detailed financial statements (balance sheet, income statement data), management's discussion and analysis (MDA) of the results, operational highlights, and events subsequent to the closing date. Although it mentions the publication of a report, the document itself provides the substantive financial data and analysis required for an interim report, thus qualifying it as an Interim/Quarterly Report (IR) rather than just an announcement. H1 2024
2024-09-12 French
20240912_TheraVet_Rapport Financier semestriel 2024.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL 2024' (Semi-Annual Financial Report 2024) and contains comprehensive financial statements, management analysis, and notes for the six-month period ending June 30, 2024. It includes detailed tables of financial data (balance sheet, income statement, cash flow) and management commentary, distinguishing it from a mere announcement or certification. Therefore, it is classified as an Interim/Quarterly Report. H1 2024
2024-09-12 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.